Ascendis Pharma A/S (ASND) Stock Price, Financials & Summary

Price chart

Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4Nov 9Nov 12

Key dataNov 12, 2026

Open$264.73

From 52W high−4.14%

Volume13569.00

Market cap$17.48B

P/E (TTM)19.7x

P/S (TTM)14.9x

Div yield—

Key dataNov 12, 2026

Open

$264.73

From 52W high

−4.14%

Volume

13569.00

Market cap

$17.48B

ValuationView details →

P/E (Fwd)

33.1x

EV/EBITDA

195.8x

P/E (TTM)

19.7x

RSI (14)

65.4

MomentumView details →

1D Return

+2.48%

YTD Return

+21.97%

SummaryUpdated Jun 1, 2026

Ascendis Pharma A/S (NASDAQ:ASND) is a Danish biopharmaceutical company founded in 2006 and headquartered in Hellerup, Denmark. The company went public on NASDAQ in January 2015. Ascendis specializes in developing innovative therapeutics for rare endocrine diseases using its proprietary TransCon technology platform, which enables the creation of long-acting versions of existing drugs. The company has successfully commercialized two products and maintains a robust pipeline of treatments targeting unmet medical needs in endocrinology and oncology.

Ask drillr about Ascendis Pharma A/S →

ValuationView details →

P/E (Fwd)

33.1x

P/E (TTM)

19.7x

EV/EBITDA

195.8x

EV/Sales

14.5x

P/S (TTM)

14.9x

P/B (TTM)

10.9x

ProfitabilityView details →

Gross Margin

90.19%

Net Margin

71.69%

EBITDA Margin

7.41%

ROE (TTM)

52.64%

ROA (TTM)

33.08%

Asset Turnover

0.49x

GrowthView details →

Revenue YoY

+114.85%

EPS YoY

+365.93%

FCF YoY

+297.19%

Revenue CAGR 3Y

+138.21%

EPS CAGR 3Y

+44.56%

EBITDA YoY

+151.76%

MomentumView details →

1D Return

+2.48%

YTD Return

+21.97%

1Y Return

+30.55%

RSI (14)

65.4

vs 50D SMA

+7.21%

vs 200D SMA

+8.65%

Capital & dividendView details →

Debt/Equity

0.31x

Current Ratio

2.99x

Quick Ratio

2.32x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$3.29

EPS Surprise

117.88%

Beats (12Q)

7/12

Next Q EPS Est

$1.20

Avg Surprise (4Q)

−245.44%

Rev Surprise

1.18%

Financials snapshotView financials →

Revenue (TTM)

1.05B

Net Income (TTM)

755.85M

Op. CF (TTM)

351.32M

Next earningsNov 12, 2026 →

Latest newsMore news →

Ascendis Pharma announced that it plans to report its third-quarter 2026 financial results and provide a business update on November 12, 2026, before U.S. markets open, followed by a conference call and webcast at 8:00 a.m. ET.7d ago

Similar companies

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.02315.HK Exelixis, Inc.EXEL 特宝生物688278.SH Shanghai Junshi Biosciences Co., Ltd.01877.HK Jazz Pharmaceuticals plcJAZZ 康希诺688185.SH Find similar companies →

Latest newsMore news →

Ascendis Pharma A/S reported third-quarter 2026 product revenue of €366 million, up 89% year over year, including €291 million for YORVIPATH, €59 million for SKYTROFA and €16 million for YUVIWEL.2h ago Ascendis Pharma announced that it plans to report its third-quarter 2026 financial results and provide a business update on November 12, 2026, before U.S. markets open, followed by a conference call and webcast at 8:00 a.m. ET.7d ago